Research Article
Outcomes of Living Kidney Donor Candidates and Living Kidney Recipient Candidates with JC Polyomavirus and BK Polyomavirus Viruria
Table 3
Demographical and clinical data of living kidney transplanted patients.
| | Living kidney recipients | N = 26 |
| | Male (n/%) | 17/65.4 | | Age (mean; SD) (years) | 45 ± 12.4 (23–69) | | Length of follow-up (mean; SD) (months) | 36.5 ± 21.5 (9–79) |
| | Induction IMS (n/%) | | No induction | 2/7.7 | | Bas + TAC + MMF + Pred | 14/53.8 | | TIMO + TAC + MMF + Pred | 10/38.5 |
| | Maintenance IMS (n/%) | | TAC + MMF + Pred | 19/73 | | EVE + MMF + Pred | 7/27 | | Donor CMV IgG+ (n/%) | 20/76.9 | | Recipient CMV IgG+ (n/%) | 19/73 | | Valganciclovir prophylaxis (n/%) | 17/63 |
| | HLA mismatches with the donor (mean ± SD) | | A or B | 2.15 ± 2.1 | | DR | 1.2 ± 0.7 |
| | Anti-HLA antibodies (n/%) | | Class I | 10/38.5 | | Cass II | 13/50 | | Class I + II | 9/34.6 |
|
|
SD: standard deviation; IMS: immunosuppression; Bas: basiliximab; TAC: tacrolimus; MMF: mycophenolate mofetil; Pred: prednisone: TIMO: thymoglobulin; EVE: everolimus; CMV: cytomegalovirus; IgG: immunoglobulin G; HLA: human leukocyte antigen.
|
